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  S
evere acute respiratory 
syndrome (SARS) ﬁ  rst emerged 
in Guangdong Province, the 
People’s Republic of China, in 
November 2002. The disease was 
characterised by a rapidly progressive 
atypical pneumonia [1]. In addition 
to other pathogens, a coronavirus not 
previously discovered was identiﬁ  ed 
in patients with SARS. Reproduction 
of a similar disease in cynomolgus 
macaques with this virus completed 
Koch’s postulates, implicating SARS 
coronavirus (SARS-CoV) as the 
aetiologic agent [2,3]. 
  Pathogenesis  of  SARS
    In typical cases, which were largely 
conﬁ  ned to adult and elderly 
individuals, SARS presented 
with acute respiratory distress 
syndrome (ARDS)—characterised 
by the presence of diffuse alveolar 
damage (DAD) upon autopsy. The 
pathological changes in lung alveoli 
most likely follow a common pathway 
characterised by an acute phase of 
protein-rich alveolar ﬂ  uid inﬂ  ux into 
the alveolar lumina as a consequence 
of the injury to the alveolar wall. 
Subsequently, type-2 pneumocyte (see 
Glossary) hyperplasia occurs to replace 
the loss of infected type-1 pneumocytes 
and to cover the denuded epithelial 
basement membrane, resulting in 
restoration of the normal alveolar 
architecture. Severe alveolar injury 
may lead to ﬁ  brosis with loss of alveolar 
function in more protracted cases. 
    SARS-CoV was detected not only in 
the respiratory tract but also in faeces 
and urine of patients. Replication of 
the virus in the gastrointestinal tract 
was conﬁ  rmed by electron microscopic 
studies of biopsies of the upper and 
lower intestinal mucosae of patients 
with SARS. Faecal transmission proved 
to be important in at least one major 
community outbreak in Hong Kong, in 
which over 300 patients were infected 
within a few days [1].
    Animal Models for SARS
    Development of animal models for 
SARS-CoV infection of humans is of 
utmost importance to elucidate the 
pathogenesis of SARS and to develop 
intervention strategies against the 
infection. A wide range of animal 
species is susceptible to experimental 
infection with SARS-CoV, including 
rodents (mice and hamsters), 
carnivores (ferrets and cats), and 
nonhuman primates (cynomolgus and 
rhesus macaques, common marmosets, 
and African green monkeys) [3–11]. 
Adult mice infected with varying 
doses of SARS-CoV in the respiratory 
tract show no clinical signs of disease, 
although the virus replicates in 
respiratory tissues, peaking early after 
infection, with viral titres in the lungs 
reaching relatively high levels. The 
infection is accompanied by only mild 
inﬂ  ammatory changes of the respiratory 
tract. On the other hand, aged mice, as 
well as hamsters and ferrets, do show 
signs of clinical disease (weight loss and 
rufﬂ  ed fur), albeit, in most cases, in the 
absence of the typical lung lesions seen 
in humans with SARS [4–6]. 
    In contrast, SARS-CoV inoculation 
in the respiratory tract of cynomolgus 
macaques causes infection of bronchial 
epithelial cells, type-1 and type-2 
pneumocytes at one to four days 
postinfection, followed by extensive 
type-2 pneumocyte hyperplasia in the 
lungs at four to six days postinfection 
[3,11]. Moreover, multiple foci of acute 
DAD are observed, characterised by 
ﬂ  ooding of alveoli with protein-rich 
oedema ﬂ  uid mixed with variable 
numbers of neutrophils and rare 
syncytia (Figure 1), and by extensive 
loss of epithelium from alveolar and 
bronchiolar walls. These lesions are 
quite similar to those observed in 
humans in the acute stages of SARS. 
Although clinical signs (respiratory 
distress and general malaise) were 
observed, they were not further studied 
in the initial experiments. 
    Studies from different laboratories 
conﬁ  rmed that nonhuman primates 
could be infected experimentally with 
SARS-CoV, although the severity of 
the induced lung pathology varied 
and clinical signs were generally not 
reported. So far, factors underlying these 
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  Figure 1.   Histologic Lesions in Lungs from 
Cynomolgus Macaques Experimentally 
Infected with SARS-CoV 
      Syncytia (indicated by the arrowhead) in the 
lumen of a bronchiole (A) and expression of 
SARS-CoV antigen by a syncytium in the lumen 
of an alveolar duct (B). 
    (Figure derived from Figures 1 and 3 in [3]; 
Photos: Thijs Kuiken) 
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differences have not been delineated, 
but virus strain, age, microbiological 
state, genetic background, and origin of 
the animals could have played a role. 
    In this issue of   PLoS Medicine,   James 
Lawler, Jason Paragas, and colleagues 
provide further support for the use of 
the cynomolgus macaque model to 
study the pathogenesis of SARS and to 
test intervention strategies [12]. They 
show that infection of these macaques 
with a molecularly cloned SARS-
CoV resulted in a mild-to-moderate 
symptomatic illness, indistinguishable 
from the illness induced with wild-
type SARS-CoV. Chest radiographs 
from several infected animals showed 
unifocal or multifocal pneumonia 
that peaked between eight to ten days 
postinfection. The authors point out 
that the results are reminiscent of the 
milder syndrome observed in younger 
humans infected with SARS-CoV. 
Molecular modiﬁ  cation of the cloned 
virus may now further allow deciphering 
of the role of different viral gene 
products in the pathogenesis of SARS. 
An important result of this present 
study is the observation that one group 
of animals inoculated via the nasal 
and ocular route exhibited signiﬁ  cant 
faecal shedding of SARS-CoV. Thus far, 
efforts to evaluate the efﬁ  cacy of SARS-
CoV vaccines have largely aimed at 
protecting the respiratory tract. 
    Implications for Future SARS 
Research
    The persistent threat of a possible 
new introduction of SARS-CoV or of a 
related virus in the human population 
necessitates further reﬁ  nement 
of animal models to elucidate the 
pathogenesis of, and intervention 
strategies against, SARS. Although none 
of the current animal models have fully 
reproduced all features of SARS, the 
most important aspects of SARS are 
observed in experimentally infected 
nonhuman primates. Such models have 
already demonstrated the protective 
effect of pre- and postexposure use 
of pegylated human interferon-α, of 
candidate SARS-CoV vaccines, and of 
convalescent sera from SARS patients 
(unpublished results; [10,11]). In the 
absence of ongoing human SARS-CoV 
infections, candidate SARS vaccines 
may have to be approved on the basis 
of animal data alone, preferably in 
two different species (the “two animal 
rule”). But in order for such approval, 
the pathophysiological mechanisms 
underlying SARS pathogenesis and 
the preventive efﬁ  cacy of such vaccines 
need to be well understood. The 
present study further supports the use 
of nonhuman primate SARS models 
for pathogenesis studies and for the 
development of intervention strategies. 
Infection of cynomolgus macaques with 
recombinant SARS-CoV containing 
deﬁ  ned modiﬁ  cations may allow further 
elucidation of SARS.   
 Glossary
   Type-1  Pneumocytes:  These cells are 
responsible for alveolar gas exchange. 
They cannot replicate and are susceptible 
to a large number of toxic insults. 
   Type-2 Pneumocytes:  These cells are 
responsible for producing and secreting 
surfactant. They can replicate in the alveoli 
to replace damaged type-1 pneumocytes. 
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